Status: Recruiting
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström's macroglobulinemia (WM).
Participants needed: 490
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Merck Sharp & Dohme LLCUpdated: Jun 12, 2026Locations: 121
Eligibility criteria
Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 wi... [+25]
Has active HBV/HCV infection (Part 1 and Part 2) [+7]